A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL.
Fenton RG, et al. Among authors: madara k.
J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74. doi: 10.1097/00002371-199609000-00006.
J Immunother Emphasis Tumor Immunol. 1996.
PMID: 8941876
Clinical Trial.